A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

The antibody-drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety, maximum-tolerated dose (MTD), and activity of weekly dosing...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical cancer research Vol. 18; no. 1; p. 248
Main Authors:	Fanale, Michelle A, Forero-Torres, Andres, Rosenblatt, Joseph D, Advani, Ranjana H, Franklin, Anna R, Kennedy, Dana A, Han, Tae H, Sievers, Eric L, Bartlett, Nancy L
Format:	Journal Article
Language:	English
Published:	United States 01.01.2012
Subjects:	Adolescent Adult Aged Aged, 80 and over Child Dose-Response Relationship, Drug Female Follow-Up Studies Hematologic Neoplasms - drug therapy Hematologic Neoplasms - mortality Humans Immunoconjugates - pharmacokinetics Immunoconjugates - therapeutic use Ki-1 Antigen - metabolism Male Maximum Tolerated Dose Middle Aged Prognosis Survival Rate Tissue Distribution Young Adult
ISSN:	1078-0432, 1557-3265, 1557-3265
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!